Developing the EAVE III platform for future health crises

Authors: Simpson, Colin R. ;

Robertson, Chris;

Jim McMenamin;

Ritchie, Lewis;

Sheikh, Aziz

Source: The Lancet Infectious Diseases

Full text

: https://doi.org/10.1016/S1473-3099(23)00626-6

Abstract

The Scottish Early Estimation of Pandemic Influenza Antiviral and Vaccine Effectiveness (EAVE) platform was established in 2012 through funding from the National Institute for Health Research, alongside a portfolio of nine pandemic preparedness and responsiveness projects consequent to the 2009 influenza A/H1N1 pandemic. In response to the emergence of COVID-19, funding was made available by a range of UK funders to support studies that could rapidly respond to this new pandemic. No precedent existed for a whole-country population platform; therefore, funding from the UK Research and Innovation–Medical Research Council and the Scottish Government was used to bring the EAVE platform out of hibernation and create the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, the first national, real-time, multidimensional, surveillance platform.

Rights

This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Simpson, C., Robertson, C., McMenamin, J., Ritchie, L. & Sheikh, A. 2023, 'Developing the EAVE III platform for future health crises', The Lancet Infectious Diseases, 23(11), pp. 1223-1225. https://doi.org/10.1016/S1473-3099(23)00626-6

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1016/S1473-3099(23)00626-6